Non-hygroscopic Lipidic Matrix for Moisture-Sensitive Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled release formulations for topiramate are limited by instability in the presence of moisture, and existing osmotic drug delivery systems have drawbacks such as limited excipient selection and low drug loading, making them unsuitable for effective and stable administration of topiramate and other moisture-sensitive agents.
Innovation Solution
A compressed tablet formulation using a non-hygroscopic lipidic matrix-forming excipient with a melting point greater than 40°C, combined with a water-soluble channel-forming excipient and a filler, which minimizes exposure to moisture and allows for controlled release of topiramate, while also incorporating an immediate release layer for phentermine using the same excipients and manufacturing method.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If traditional osmotic drug delivery systems are used for controlled release of topiramate, then controlled release function is achieved, but the formulation has limited excipient selection and low drug loading
Solution Approach 1:
The patent changes the physical-chemical parameters of the excipients by selecting non-hygroscopic materials with specific melting points (>40°C) and solubility characteristics. This allows the formulation to achieve controlled release while expanding excipient selection beyond traditional osmotic systems, resolving the contradiction between controlled release duration and excipient versatility.
Solution Approach 2:
The patent creates a composite tablet formulation combining non-hygroscopic lipidic matrix-forming excipients, non-hygroscopic water-soluble channel-forming excipients, and filler materials. This composite structure enables both controlled release functionality and enhanced excipient selection flexibility, overcoming the limitations of traditional single-system osmotic formulations.
2Duration of action of moving object
If traditional osmotic drug delivery systems are used for controlled release of topiramate, then controlled release function is achieved, but the formulation has low drug loading
Solution Approach 1:
The patent modifies the formulation parameters by using non-hygroscopic excipients with higher melting points and adjusted solubility profiles. This enables increased drug loading while maintaining controlled release characteristics, as the excipient matrix can accommodate higher drug concentrations without compromising the controlled release mechanism.
3Stability of the object's composition
If hygroscopic excipients are used in controlled release formulation, then formulation stability is improved, but moisture-sensitive agents like topiramate degrade
Solution Approach 1:
The patent converts the potential harm of moisture sensitivity into a benefit by deliberately selecting non-hygroscopic excipients that resist moisture absorption. This protective approach prevents moisture-induced degradation of topiramate while maintaining formulation stability, transforming the vulnerability to moisture into a strength through careful excipient selection.
Solution Approach 2:
The patent creates an inert formulation environment by using non-hygroscopic excipients that do not absorb moisture from the atmosphere. This inert approach protects the moisture-sensitive topiramate agent from degradation while maintaining overall formulation stability, effectively isolating the drug from harmful moisture interactions.
4Speed
If immediate release formulation is used for phentermine, then rapid onset is achieved, but controlled release function is lost
Solution Approach 1:
The patent segments the tablet into distinct functional layers: an immediate release layer for phentermine providing rapid onset, and a controlled release layer for topiramate providing sustained duration. This segmentation allows each layer to fulfill its specific temporal requirement, resolving the contradiction between rapid onset and prolonged duration.
Solution Approach 2:
The patent applies local quality by giving different regions of the tablet different release characteristics. The phentermine-containing layer is formulated for immediate release with rapid dissolution, while the topiramate-containing layer is formulated for controlled release. This spatial differentiation of properties enables simultaneous achievement of rapid onset and sustained duration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides enhanced stability and controlled release of topiramate, maintaining efficacy while reducing side effects, and can be used for other moisture-sensitive agents, offering a more stable and efficient delivery method compared to traditional osmotic systems.
Implementation Method 1
a non-hygroscopic, water-soluble, channel-forming excipient
Implementation Method 2
a non-hygroscopic, lipidic matrix-forming excipient having a melting point greater than about 40° C.
Implementation Method 3
The table is substantially free of hygroscopic excipients
Data Source
AI summary
Drug tablets that include a controlled release layer of a moisture-sensitive active agent are prepared with a lipidic matrix forming excipient, a water-soluble, channel forming excipient and a filler, each being non-hygroscopic. The tablets are formed in a process where the components are blended in the absence of moisture and in particulate form.